2021
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity
Anfray C, Mainini F, Digifico E, Maeda A, Sironi M, Erreni M, Anselmo A, Ummarino A, Gandoy S, Expósito F, Redrado M, Serrano D, Calvo A, Martens M, Bravo S, Mantovani A, Allavena P, Andón FT. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity. Journal For ImmunoTherapy Of Cancer 2021, 9: e002408. PMID: 34531246, PMCID: PMC8449972, DOI: 10.1136/jitc-2021-002408.Peer-Reviewed Original ResearchConceptsT cellsSingle treatmentAntitumoral efficacyImmune responseProteomics experimentsProtein-protein interaction analysisFlow cytometryM-CSF-differentiated macrophagesInteraction network analysisAntitumor immune responseRecruitment of CD4Tumor-infiltrating leukocytesAntitumoral immune responseImmunocompetent murine modelInfiltration of macrophagesQuantitative proteomics experimentsLung cancer modelMacrophage cytotoxic activityT cell proliferationTumor-associated macrophagesTLR agonist treatmentCytotoxic activityAntitumor effectorsAntitumoral immunityTumor rechallenge
2019
Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response
Sahraei M, Chaube B, Liu Y, Sun J, Kaplan A, Price NL, Ding W, Oyaghire S, García-Milian R, Mehta S, Reshetnyak YK, Bahal R, Fiorina P, Glazer PM, Rimm DL, Fernández-Hernando C, Suárez Y. Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. Journal Of Clinical Investigation 2019, 129: 5518-5536. PMID: 31710308, PMCID: PMC6877327, DOI: 10.1172/jci127125.Peer-Reviewed Original ResearchConceptsTumor-associated macrophagesMiR-21 expressionTumor growthMiR-21Immune responseCytotoxic T cell responsesC motif chemokine 10Antitumor immune responseT cell responsesAntitumoral immune responseTumor immune infiltratesInduction of cytokinesPotential therapeutic implicationsMiR-21 inhibitionStages of carcinogenesisAngiostatic phenotypeTumor cell deathIL-12Immune infiltratesTherapeutic implicationsSolid tumorsTumor neovascularizationTumor progressionTumor microenvironmentTumor pathogenesis
2018
Harnessing the Immunomodulatory Effects of Radiation Therapy.
Campbell AM, Decker RH. Harnessing the Immunomodulatory Effects of Radiation Therapy. Oncology 2018, 32: 370-4, cv3. PMID: 30080922.Peer-Reviewed Original ResearchConceptsImmunomodulatory effectsImmune responseImmune systemSetting of cancerSystemic immune responsesAntitumoral immune responseInnate immune systemAdaptive immune systemCell deathTumor cell deathAntitumoral immunityAntitumoral responseHypofractionated radiationRadiotherapy timingProinflammatory responsePreclinical modelsAdaptive immunityRadiation therapyClinical informationRadiation-induced cell deathDoseImmunityDeathPotential superiorityDNA damage
2016
PD-1 marks dysfunctional regulatory T cells in malignant gliomas
Lowther DE, Goods BA, Lucca LE, Lerner BA, Raddassi K, van Dijk D, Hernandez AL, Duan X, Gunel M, Coric V, Krishnaswamy S, Love JC, Hafler DA. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight 2016, 1: e85935. PMID: 27182555, PMCID: PMC4864991, DOI: 10.1172/jci.insight.85935.Peer-Reviewed Original ResearchTumor-infiltrating TregsPD-1IFN-γ productionGlioblastoma multiformeT cellsImmune responseHealthy subjectsDysfunctional regulatory T cellsHigh PD-1 expressionCell death protein 1PD-1-blocking antibodiesPD-1 expressionEffector T cellsRegulatory T cellsDeath protein 1Antitumoral immune responseImmune checkpoint receptorsProduction of IFNExhausted phenotypeExhaustion signaturesCheckpoint receptorsHuman TregsTumor infiltratesFunctional statusMalignant gliomas
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply